

treatment by transdermal delivery from the transdermal system of claim 1.

#### REMARKS

By the foregoing amendments, the specification has been revised to better conform with U.S. practice, as has claim 1. Translated claims 2-15, having been canceled in the preliminary amendment of November 29, 1999, have been substituted for by new claims 16-29 corresponding to original translated claims 2-15, respectively. Use claim 15 has been rewritten as a method claim, consistent with U.S. practice, and multiple dependencies have been omitted from the claims.


Entry and consideration of the foregoing amendments are solicited.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,  
MURRAY & BORUN

May 5, 2000

By

  
\_\_\_\_\_  
James P. Zeller  
Reg. No. 28,491

6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

REMARKS


By the foregoing, the number of claims has been reduced to minimize the filing fee. The filing fee for this application is based on the claims as amended above.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,  
MURRAY & BORUN

November 29, 1999

By

  
\_\_\_\_\_  
James P. Zeller  
Reg. No. 28,491

6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300